Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.54 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21694180 | 1.00 | CYP1A2 (0.85) | CYP1A2CYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL10408892 | 1.00 | CYP1A2 (0.85) | CYP1A2CYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL18049454 | 1.00 | CYP1A2 (0.85) | CYP1A2CYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL3523843 | 1.00 | CYP1A2 (0.85) | CYP1A2CYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL8389395 | 1.00 | CYP1A2 (0.85) | CYP1A2CYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL4950279 | 1.00 | CYP1A2 (0.85) | CYP1A2CYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL10430130 | 1.00 | CYP1A2 (0.85) | CYP1A2CYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL5085710 | 1.00 | CYP1A2 (0.85) | CYP1A2CYP2C9CYP2C19ALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL4942615 | 0.98 | CYP1A2 (0.82) | CYP1A2CYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL1341248 | 0.98 | CYP1A2 (0.89) | CYP1A2CYP2C9CYP2C19ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110499164-B | Liquid crystal alignment agent, liquid crystal alignment film and liquid crystal display element | 奇美实业股份有限公司 | 2023-12-05 | — | — | CN | disclosed |
| CN-107880902-B | Liquid crystal alignment agent, liquid crystal alignment film and liquid crystal display assembly | 奇美实业股份有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-108003896-B | Liquid crystal alignment agent, liquid crystal alignment film and liquid crystal display element | 奇美实业股份有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-109085722-B | Method for manufacturing liquid crystal alignment film and liquid crystal display element | 奇美实业股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-109207170-B | Liquid crystal alignment agent, liquid crystal alignment film and liquid crystal display element | 奇美实业股份有限公司 | 2021-12-10 | — | — | CN | disclosed |
| WO-2020032090-A1 | EPOXY COMPOUND, EPOXY RESIN, EPOXY RESIN COMPOSITION, CURED RESIN PRODUCT, PREPREG, FIBER-REINFORCED COMPOSITE MATERIAL, AND PRODUCTION METHOD FOR THESE | 帝人株式会社 | 2020-02-13 | — | — | WO | disclosed |
| EP-2277595-A2 | Compounds for immunopotentiation | Novartis Vaccines and Diagnostics, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| EP-1765313-A2 | COMPOUNDS FOR IMMUNOPOTENTIATION | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006002422-A9 | COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORP (US) | 2006-09-21 | — | — | WO | disclosed |
| EP-0970070-B1 | PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 2004-10-06 | — | — | EP | disclosed |
| US-6710047-B2 | INHIBIT THE ACTIVITY OF THE VEGF RECEPTOR TYROSINE KINASE AND THE GROWTH OF TUMOURS | NOVARTIS AG (CH) | 2004-03-23 | — | — | US | disclosed |
| US-20030191129-A1 | Phthalazines with angiogenesis inhibiting activity | BOLD GUIDO (CH) | 2003-10-09 | — | — | US | disclosed |
| US-6514974-B2 | 1-(4-Chloroanilino)-4-(4-pyridylmethyl)phthalazine for example | NOVARTIS AG (CH) | 2003-02-04 | — | — | US | disclosed |
| US-20020091261-A1 | Phthalazines with angiogenesis inhibiting activity | BOLD GUIDO (CH) | 2002-07-11 | — | — | US | disclosed |
| US-6258812-B1 | ANGIOGENESIS INHIBITORS, ANTITUMOR AGENTS AND CARDIOVASCULAR DISORDERS | NOVARTIS AG (CH) | 2001-07-10 | — | — | US | disclosed |
| EP-0970070-A1 | PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | Novartis AG (CH) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998035958-A1 | PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1998-08-20 | — | — | WO | disclosed |
| EP-0116931-B1 | DIARYLOXAL AMIDES AND THEIR USE AS UV ABSORBERS, AND POLYMERIC SUBSTRATES CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1986-08-06 | — | — | EP | disclosed |
| EP-0116931-A1 | Diaryloxal amides and their use as UV absorbers, and polymeric substrates containing them | BASF Aktiengesellschaft (DE) | 1984-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191129-A1 | Phthalazines with angiogenesis inhibiting activity | PGF, VEGFA, FLT4 | CYP1A2 1081/4885CYP2C9 2308/4885CYP2C19 2575/4885 |
| US-20100226931-A1 | Compounds for immunopotentiation | LY96, ICOS, PDCD1 | CYP1A2 3446/4885CYP2C9 3960/4885CYP2C19 2969/4885 |
| US-20020091261-A1 | Phthalazines with angiogenesis inhibiting activity | PGF, VEGFA, FLT4 | CYP1A2 1333/4885CYP2C9 2640/4885CYP2C19 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.